#ACI-24.060

Lead report

AC Immune H1 Results: Alzheimer's Vaccine Data on the Horizon, Cash Runway Secured Through 2027

AC Immune reported H1 2025 results with increased R&D spending and a cash runway into 2027. Key catalyst is the upcoming Phase IIb data for ACI-24.060, with partnerships with Roche and Lilly advancing.